FDA：山德士召回一批氯沙坦钾氢氯噻嗪

 翻译：JULIA   来源：Julia法规翻译 FDA alerts patients and health care professionals to Sandoz’s losartan potassium and hydrochlorothiazide recall of one lot due to NDEAFDA警示患者和卫生专业人员：山德士因NDEA召回一批氯沙坦钾氢氯噻嗪Update [11/9/2018] FDA is alerting patients and health care professionals to Sandoz’s voluntary recall of one lot –JB8912 – of losartan potassium and hydrochlorothiazide 100mg/25mg tablets, that contain losartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a diuretic, used in combination for the treatment of hypertension. Sandoz’s product was made using an active pharmaceutical ingredient (API) that has tested positive for NDEA. The API was manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd, which is on import alert.更新【2018-11-09】FDA警示患者和卫生专业人员 ………………………………